Menu
Search
|

Menu

Close
X

Lexicon Pharmaceuticals Inc LXRX.OQ (NASDAQ Stock Exchange Global Select Market)

2.34 USD
-0.08 (-3.31%)
As of Sep 13
Previous Close 2.42
Open 2.37
Volume 499,230
3m Avg Volume 277,051
Today’s High 2.47
Today’s Low 2.25
52 Week High 11.50
52 Week Low 1.13
Shares Outstanding (mil) 106.27
Market Capitalization (mil) 179.60
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.17 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY19
9
FY18
63
FY17
92
FY16
79
EPS (USD)
FY19
-0.206
FY18
-1.137
FY17
-1.207
FY16
-1.266
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
3.80
7.90
Price to Book (MRQ)
vs sector
--
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
--
17.64
LT Debt to Equity (MRQ)
vs sector
--
12.61
Return on Investment (TTM)
vs sector
-38.81
12.69
Return on Equity (TTM)
vs sector
--
17.13

EXECUTIVE LEADERSHIP

Raymond Debbane
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Lonnel Coats
President, Chief Executive Officer, Director, Since 2014
Salary: $634,159.00
Bonus: $402,399.00
Jeffrey Wade
Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs, Since 2015
Salary: $436,644.00
Bonus: $158,450.00
Pablo Lapuerta
Executive Vice President, Chief Medical Officer, Since 2015
Salary: $401,482.00
Bonus: $121,646.00
Alan Main
Executive Vice President, Commercial Supply Operations, Since 2017
Salary: $369,245.00
Bonus: $138,030.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8800 Technology Forest Pl
THE WOODLANDS   TX   77381-1160

Phone: +1281.8633000

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

SPONSORED STORIES